RT Journal Article
SR Electronic
T1 SARS-CoV-2 Transmission in Alberta, British Columbia, and Ontario, Canada, January 1-July 6, 2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.18.20156992
DO 10.1101/2020.07.18.20156992
A1 Isaac Chun-Hai Fung
A1 Yuen Wai Hung
A1 Sylvia K. Ofori
A1 Kamalich Muniz-Rodriguez
A1 Po-Ying Lai
A1 Gerardo Chowell
YR 2020
UL http://medrxiv.org/content/early/2020/08/26/2020.07.18.20156992.abstract
AB Objective To investigate COVID-19 epidemiology in Alberta, British Columbia and Ontario, Canada.Methods We calculated the incidence rate ratio (January 1—July 6, 2020) between the 3 provinces, and estimated time-varying reproduction number, Rt, starting from March 1, using EpiEstim package in R.Results Using British Columbia as a reference, the incidence rate ratios in Alberta and Ontario are 3.1 and 4.3 among females, and 3.4 and 4.0 among males. In Ontario, Rt fluctuated ~1 in March, reached values >1 in early and mid-April, then dropped <1 in late April and early May. Rt rose to ~1 in mid-May and then remained <1 from late May through early July. In British Columbia, Rt dropped <1 in early April, but it increased towards the end of April. Rt <1 in May while it fluctuated around 1.0 in June and early July. In Alberta, Rt > 1 in March; Rt dropped in early April and rose again in late April. In much of May, Rt <1, but Rt increases in early June and fluctuates ~1 since mid-June.Conclusions Rt wavering around 1.0 indicated that three provinces of Canada have managed to achieve limited onward transmission of SARS-CoV-2 as of early July 2020.Competing Interest StatementThe authors have declared no competing interest.Funding StatementG.C. received support from NSF grant 1414374 as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program. I.C.-H.F. received salary support from the Centers for Disease Control and Prevention (CDC) (19IPA1908208). This article is not part of I.C.-H.F's CDC-sponsored projects.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics. The Georgia Southern University Institutional Review Board made a nonhuman subjects determination for this project (H20364), under the G8 exemption category.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data used are publicly available data downloaded from websites of the provincial governments of Alberta, British Columbia and Ontario. The URL links to those websites are provided in the reference list of the manuscript.